Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $576,040 | 88 | 93.8% |
| Travel and Lodging | $24,254 | 44 | 3.9% |
| Honoraria | $10,256 | 1 | 1.7% |
| Food and Beverage | $3,061 | 49 | 0.5% |
| Unspecified | $600.00 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $370,650 | 53 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $147,862 | 84 | $0 (2023) |
| H. Lundbeck A S | $20,077 | 4 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $15,199 | 4 | $0 (2019) |
| Janssen Research & Development, LLC | $14,740 | 1 | $0 (2019) |
| Sage Therapeutics, Inc. | $7,504 | 5 | $0 (2024) |
| Eli Lilly and Company | $6,108 | 7 | $0 (2019) |
| Lundbeck LLC | $4,620 | 3 | $0 (2017) |
| Biogen, Inc. | $3,566 | 2 | $0 (2019) |
| F. Hoffmann-La Roche AG | $3,495 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $126,331 | 12 | Eisai Inc. ($122,936) |
| 2023 | $84,315 | 12 | Eisai Inc. ($72,602) |
| 2022 | $94,658 | 16 | EISAI INC. ($83,363) |
| 2021 | $80,502 | 13 | Eisai Inc. ($69,495) |
| 2020 | $60,985 | 21 | ACADIA Pharmaceuticals Inc ($54,924) |
| 2019 | $57,072 | 25 | ACADIA Pharmaceuticals Inc ($23,861) |
| 2018 | $51,677 | 51 | ACADIA Pharmaceuticals Inc ($49,452) |
| 2017 | $58,671 | 33 | H. Lundbeck A S ($20,077) |
All Payment Transactions
183 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $8,741.66 | General |
| Category: Neurology | ||||||
| 12/01/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $21,488.74 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $14,346.18 | General |
| Category: Neurology | ||||||
| 10/03/2024 | Abbott Laboratories | EPIC (Device) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Structural Heart | ||||||
| 08/23/2024 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $536.00 | General |
| 08/08/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $19,745.00 | General |
| Category: Neurology | ||||||
| 07/20/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $28,486.20 | General |
| Category: Neurology | ||||||
| 07/01/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $6,283.57 | General |
| Category: Neurology | ||||||
| 06/14/2024 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $536.00 | General |
| 06/10/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $11,922.24 | General |
| Category: Neurology | ||||||
| 05/10/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $11,922.24 | General |
| Category: Neurology | ||||||
| 11/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 10/17/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,715.00 | General |
| 09/22/2023 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,144.00 | General |
| 09/01/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,645.00 | General |
| 07/25/2023 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $10,530.21 | General |
| Category: Neurology | ||||||
| 07/07/2023 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,144.00 | General |
| 06/05/2023 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $14,832.36 | General |
| Category: Neurology | ||||||
| 05/13/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $64.17 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/05/2023 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $14,832.36 | General |
| Category: Neurology | ||||||
| 04/04/2023 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $14,832.36 | General |
| Category: Neurology | ||||||
| 03/03/2023 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $14,218.03 | General |
| Category: Neurology | ||||||
| 01/11/2023 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $3,357.06 | General |
| Category: Neurology | ||||||
| 12/02/2022 | EISAI INC. | — | Consulting Fee | Cash or cash equivalent | $3,357.06 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, SEQUENTIAL COHORTS, FLEXIBLE DOSE STUDY TO EVALUATE THE TOLERABILITY, SAFETY AND PHARMACOKINETICS OF ILOPERIDONE IN ELDERLY PATIENTS WITH PARKINSON'S DISEASE PSYCHOSIS (PDP) | Vanda Pharmaceuticals Inc. | $600.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 12 | $2,108 | $1,614 |
| 2020 | 1 | 16 | 16 | $4,525 | $2,106 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 12 | 12 | $2,108 | $1,614 | 76.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 16 | 16 | $4,525 | $2,106 | 46.5% |
About Dr. Daniel Weintraub, MD
Dr. Daniel Weintraub, MD is a Psychiatry healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306865779.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Weintraub, MD has received a total of $614,211 in payments from pharmaceutical and medical device companies, with $126,331 received in 2024. These payments were reported across 183 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($576,040).
As a Medicare-enrolled provider, Weintraub has provided services to 28 Medicare beneficiaries, totaling 28 services with total Medicare billing of $3,720. Data is available for 2 years (2020–2023), covering 2 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Other Specialties Geriatric Psychiatry
- Location Philadelphia, PA
- Active Since 07/18/2006
- Last Updated 09/04/2015
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1306865779
Products in Payments
- Leqembi (Drug) $195,538
- NUPLAZID (Drug) $134,494
- DISEASE EDUCATION (Drug) $12,500
- Non-Covered Product (Drug) $4,255
- Dayvigo (Drug) $3,240
- VRAYLAR (Drug) $2,300
- FANAPT (Drug) $600.00
- NORTHERA (Drug) $140.12
- QUVIVIQ (Drug) $129.30
- EPIC (Device) $23.55
- REMICADE (Biological) $22.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Philadelphia
Dr. Michael Thase, Md, MD
Psychiatry — Payments: $418,426
Dr. Karl Doghramji, Md, MD
Psychiatry — Payments: $130,409
Richard Jaffe, Md, MD
Psychiatry — Payments: $126,747
Kyle Kampman, Md, MD
Psychiatry — Payments: $118,739
Ramesh Eluri, M.d, M.D
Psychiatry — Payments: $88,982
John Lauriello, Md, MD
Psychiatry — Payments: $75,274